Charles S. Berkman
Net Worth

Last updated:

What is Charles S. Berkman net worth?

The estimated net worth of Mr. Charles S. Berkman is at least $28,021,576 as of 4 Feb 2021. He owns shares worth $4,308,439 as insider, has earned $14,965,097 from insider trading and has received compensation worth at least $8,748,040 in Ligand Pharmaceuticals Incorporated.

What is the salary of Charles S. Berkman?

Mr. Charles S. Berkman salary is $624,860 per year as Senior Vice President, Gen. Counsel & Sec. in Ligand Pharmaceuticals Incorporated.

How old is Charles S. Berkman?

Mr. Charles S. Berkman is 56 years old, born in 1969.

What stocks does Charles S. Berkman currently own?

As insider, Mr. Charles S. Berkman owns shares in one company:

Company Title Shares Price per share Total value
Ligand Pharmaceuticals Incorporated (LGND) Senior Vice President, Gen. Counsel & Sec. 28,906 $149.05 $4,308,439

What does Ligand Pharmaceuticals Incorporated do?

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.

LGND logo
LGND
Ligand Pharmaceuticals Incorporated
$149.05

Charles S. Berkman insider trading

Ligand Pharmaceuticals Incorporated

Mr. Charles S. Berkman has made 16 insider trades between 2011-2021, according to the Form 4 filled with the SEC. Most recently he sold 18,097 units of LGND stock worth $3,230,369 on 4 Feb 2021.

The largest trade he's ever made was exercising 37,331 units of LGND stock on 30 Aug 2013. As of 4 Feb 2021 he still owns at least 28,906 units of LGND stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 18,097 $178.5 $3,230,369
Sale
Common Stock 11,146 N/A N/A
Option
Employee Stock Option (right to buy) 1,093 $71.03 $77,630
Option
Common Stock 1,093 $71.03 $77,630
Option
Common Stock 2,850 $50.87 $144,971
Option
Employee Stock Option (right to buy) 919 $39.09 $35,924
Option
Employee Stock Option (right to buy) 3,400 $21.92 $74,528
Option
Common Stock 3,400 $21.92 $74,528
Option
Employee Stock Option (right to buy) 1,212 $21.92 $26,567
Option
Common Stock 3,900 $18.2 $70,961
Option
Incentive Stock Option (right to buy) 2,688 $14.47 $38,895
Option
Common Stock 2,000 $14.47 $28,940
Option
Incentive Stock Option (right to buy) 2,000 $14.47 $28,940
Option
Common Stock 2,813 $100.38 $282,369
Sale
Common Stock 2,813 $100.38 $282,369
Option
Employee Stock Option (right to buy) 2,813 $100.38 $282,369
Sale
Common Stock 19,417 $254.99 $4,951,063
Option
Common Stock 19,417 $59.6 $1,157,214
Option
Non-Qualified Stock Option (right to buy) 469 $21.92 $10,280
Option
Employee Stock Option (right to buy) 18,948 $72.16 $1,367,231
Sale
Common Stock 18,625 $126.96 $2,364,667
Sale
Common Stock 4,295 $123.16 $528,972
Option
Non-Qualified Stock Option (right to buy) 4,295 $123.16 $528,972
Option
Common Stock 30,347 $90.65 $2,750,895
Option
Employee Stock Option (right to buy) 21,105 $95.73 $2,020,318
Option
Common Stock 1,000 $53.1 $53,100
Option
Employee Stock Option (right to buy) 1,000 $53.1 $53,100
Option
Employee Stock Option (right to buy) 5,625 $10.05 $56,531
Option
Incentive Stock Option (right to buy) 8,442 $14.47 $122,156
Option
Common Stock 14,067 $12.26 $172,461
Sale
Common Stock 14,067 $99.06 $1,393,519
Option
Non-Qualified Stock Option (right to buy) 4,130 $74.58 $308,015
Option
Employee Stock Option (right to buy) 1,134 $14.47 $16,409
Option
Common Stock 5,264 $44.53 $234,380
Sale
Common Stock 6,000 $74.51 $447,060
Purchase
Common Stock 126 $45.23 $5,699
Purchase
Common Stock 329 $43.79 $14,408
Option
Common Stock 2,499 $49.44 $123,558
Option
Employee Stock Option (right to buy) 486 $14.47 $7,032
Option
Non-Qualified Stock Option (right to buy) 2,013 $66.93 $134,730
Sale
Common Stock 4,667 $66.89 $312,176
Option
Common Stock 2,000 $14.47 $28,940
Option
Incentive Stock Option (right to buy) 2,000 $14.47 $28,940
Option
Common Stock 14,881 $56.7 $843,812
Option
Non-Qualified Stock Option (right to buy) 11,099 $52.99 $588,103
Option
Employee Stock Option (right to buy) 1,616 $44.49 $71,888
Sale
Common Stock 2,122 $42.23 $89,612
Purchase
Common Stock 209 $33.92 $7,088
Option
Employee Stock Option (right to buy) 33,497 $33.76 $1,130,926
Sale
Common Stock 9,499 $47.54 $451,573
Option
Common Stock 37,331 $31.64 $1,180,966
Option
Common Stock 4,284 $10.05 $43,054
Option
Incentive Stock Option (right to buy) 4,284 $10.05 $43,054
Option
Common Stock 14,583 $42.63 $621,732
Option
Non-Qualified Stock Option (right to buy) 14,583 $42.63 $621,732
Sale
Common Stock 14,583 $42.63 $621,732
Purchase
Common Stock 815 N/A N/A
Sale
Common Stock 4,000 $26.66 $106,640
Sale
Common Stock 4,249 $18.77 $79,754
Sale
Common Stock 3,606 $15.76 $56,841
Sale
Common Stock 5,000 $9.75 $48,750

Ligand Pharmaceuticals Incorporated key executives

Ligand Pharmaceuticals Incorporated executives and other stock owners filed with the SEC: